Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Takeda Pharmaceutical Company ( (TAK) ) has issued an announcement.
On July 2, 2025, Takeda Pharmaceutical Company Limited, through its subsidiary Takeda U.S. Financing, Inc., executed an indenture agreement involving the issuance of two series of guaranteed notes. The notes include $1.65 billion at 5.200% due in 2035 and $750 million at 5.900% due in 2055. This financial maneuver, involving The Bank of New York Mellon as trustee and paying agent, is expected to enhance Takeda’s financial flexibility and support its strategic initiatives.
The most recent analyst rating on (TAK) stock is a Hold with a $13.40 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Company stock, see the TAK Stock Forecast page.
Spark’s Take on TAK Stock
According to Spark, TipRanks’ AI Analyst, TAK is a Outperform.
Takeda Pharmaceutical Company demonstrates strong financial performance, driven by consistent revenue and profit growth, a solid balance sheet, and effective cash flow management. While the company’s technical indicators show moderate bullish momentum, the high P/E ratio raises valuation concerns. The mixed earnings call highlights both promising product launches and challenges from generic competition. Overall, Takeda’s strong fundamentals and promising pipeline are somewhat tempered by valuation and competitive pressures, resulting in an overall stock score of 71.
To see Spark’s full report on TAK stock, click here.
More about Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global pharmaceutical company based in Tokyo, Japan. It is primarily focused on the research, development, and commercialization of pharmaceutical products, with a strong emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Average Trading Volume: 2,312,787
Technical Sentiment Signal: Buy
Current Market Cap: $48.47B
For an in-depth examination of TAK stock, go to TipRanks’ Overview page.